内科理论与实践››2023,Vol. 18››Issue (02): 128-130.doi:10.16138/j.1673-6087.2023.02.014
张梦潇1, 韦晓2, 张少红2, 陈国芳2(
), 刘超2()
收稿日期:2021-08-09出版日期:2023-04-25发布日期:2023-05-15通讯作者:陈国芳 E-mail:
基金资助:
ZHANG Mengxiao1, WEI Xiao2, ZHANG Shaohong2, et al
Received:2021-08-09Online:2023-04-25Published:2023-05-15中图分类号:
张梦潇, 韦晓, 张少红, 陈国芳, 刘超. 生长分化因子15：减重治疗的新靶点[J]. 内科理论与实践, 2023, 18(02): 128-130.
ZHANG Mengxiao, WEI Xiao, ZHANG Shaohong, et al . Growth differentiation factor 15: a new target for weight management[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(02): 128-130.
| [1] | Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1): 24-39. doi:10.1038/s41575-020-00366-5pmid:33093663 |
| [2] | Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial[J]. Lancet, 2018, 391(10120): 541-551. doi:S0140-6736(17)33102-1pmid:29221645 |
| [3] | Baek SJ, Okazaki R, Lee SH, et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia[J]. Gastroenterology, 2006, 131(5): 1553-1560. doi:10.1053/j.gastro.2006.09.015pmid:17101328 |
| [4] | Xiong Y, Walker K, Min X, et al. Long-acting MIC-1/GDF15 molecules to treat obesity: evidence from mice to monkeys[J]. Sci Transl Med, 2017, 9(412). |
| [5] | Baek SJ, Eling T. Growth differentiation factor 15 (GDF15)[J]. Pharmacol Ther, 2019, 198: 46-58. doi:10.1016/j.pharmthera.2019.02.008URL |
| [6] | Hsu JY, Crawley S, Chen M, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15[J]. Nature, 2017, 550(7675): 255-259. doi:10.1038/nature24042URL |
| [7] | Tsai VWW, Husaini Y, Sainsbury A, et al. The MIC-1/GDF15-GFRAL pathway in energy homeostasis[J]. Cell Metab, 2018, 28(3): 353-368. doi:10.1016/j.cmet.2018.07.018URL |
| [8] | Wiklund FE, Bennet AM, Magnusson PK, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15)[J]. Aging Cell, 2010, 9(6): 1057-1064. doi:10.1111/j.1474-9726.2010.00629.xURL |
| [9] | Ahmed DS, Isnard S, Lin J, et al. GDF15/GFRAL pathway as a metabolic signature for cachexia in patients with cancer[J]. J Cancer, 2021, 12(4): 1125-1132. doi:10.7150/jca.50376pmid:33442410 |
| [10] | Yang L, Chang CC, Sun Z, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand[J]. Nat Med, 2017, 23(10): 1158-1166. doi:10.1038/nm.4394pmid:28846099 |
| [11] | Mullican SE, Lin-Schmidt X, Chin CN, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates[J]. Nat Med, 2017, 23(10): 1150-1157. doi:10.1038/nm.4392pmid:28846097 |
| [12] | Emmerson PJ, Wang F, Du Y, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL[J]. Nat Med, 2017, 23(10): 1215-1219. doi:10.1038/nm.4393pmid:28846098 |
| [13] | Tsai VW, Macia L, Johnen H, et al. TGF-b superfamily cytokine MIC-1/GDF15 is a physiological appetite and body weight regulator[J]. PLoS One, 2013, 8(2): e55174. doi:10.1371/journal.pone.0055174URL |
| [14] | Chung HK, Ryu D, Kim KS, et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis[J]. J Cell Biol, 2017, 216(1): 149-165. doi:10.1083/jcb.201607110pmid:27986797 |
| [15] | Chrysovergis K, Wang X, Kosak J, et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism[J]. Int J Obes(Lond), 2014, 38(12): 1555-1564. doi:10.1038/ijo.2014.27 |
| [16] | Frikke-Schmidt H, Hultman K, Galaske JW, et al. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice[J]. Mol Metab, 2019, 21: 13-21. doi:S2212-8778(18)31143-8pmid:30685336 |
| [17] | Dolo PR, Yao L, Liu PP, et al. Effect of sleeve gastrectomy on plasma growth differentiation factor-15 (GDF15) in human[J]. Am J Surg, 2020, 220(3):725-730. doi:S0002-9610(20)30053-2pmid:32014297 |
| [18] | Kleinert M, Bojsen-Møller KN, Jørgensen NB, et al. Effect of bariatric surgery on plasma GDF15 in humans[J]. Am J Physiol Endocrinol Metab, 2019, 316(4): E615-E621. doi:10.1152/ajpendo.00010.2019URL |
| [19] | Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin[J]. Diabetologia, 2017, 60(9): 1577-1585. doi:10.1007/s00125-017-4342-zpmid:28776086 |
| [20] | Gerstein HC, Pare G, Hess S, et al. Growth differentiation factor 15 as a novel biomarker for metformin[J]. Diabetes Care, 2017, 40(2): 280-283. doi:10.2337/dc16-1682pmid:27974345 |
| [21] | Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance[J]. Nature, 2020, 578(7795): 444-448. doi:10.1038/s41586-019-1911-y |
| [22] | Zhao J, Li M, Chen Y, et al. Elevated serum growth differentiation factor 15 levels in hyperthyroid patients[J]. Front Endocrinol (Lausanne), 2019, 9: 793. doi:10.3389/fendo.2018.00793URL |
| [23] | Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease[J]. Annu Rev Physiol, 2021, 83: 127-151. doi:10.1146/physiol.2021.83.issue-1URL |
| [24] | Tsai VW, Zhang HP, Manandhar R, et al. GDF15 mediates adiposity resistance through actions on GFRAL neurons in the hindbrain AP/NTS[J]. Int J Obes (Lond), 2019, 43(12): 2370-2380. doi:10.1038/s41366-019-0365-5 |
| [25] | Johnen H, Lin S, Kuffner T, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1[J]. Nat Med, 2007, 13(11): 1333-1340. doi:10.1038/nm1677pmid:17982462 |
| [26] | Hale C, Véniant MM. Growth differentiation factor 15 as a potential therapeutic for treating obesity[J]. Mol Metab, 2021, 46: 101117. doi:10.1016/j.molmet.2020.101117URL |
| [27] | Patel S, Alvarez-Guaita A, Melvin A, et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans[J]. Cell Metab, 2019, 29(3): 707-718. doi:S1550-4131(18)30753-8pmid:30639358 |
| [28] | Campderrós L, Moure R, Cairó M, et al. Brown adipocytes secrete GDF15 in response to thermogenic activation[J]. Obesity, 2019, 27(10): 1606-1616. doi:10.1002/oby.22584pmid:31411815 |
| [29] | Lee SE, Kang SG, Choi MJ, et al. Growth differentiation factor 15 mediates systemic glucose regulatory action of T-helper type 2 cytokines[J]. Diabetes, 2017, 66(11): 2774-2788. doi:10.2337/db17-0333pmid:28874416 |
| [30] | Eddy AC, Trask AJ. Growth differentiation factor-15 and its role in diabetes and cardiovascular disease[J]. Cytokine Growth Factor Rev, 2021, 57: 11-18. doi:10.1016/j.cytogfr.2020.11.002URL |
| [1] | 韦坤辰, 谢芸, 李青峰. 皮肤软组织扩张的相关研究进展[J]. 组织工程与重建外科杂志, 2023, 19(1): 70-. |
| [2] | 高玉莲, 冯耘, 倪磊.糖尿病人群中耐药革兰阴性菌血流感染的研究进展[J]. 内科理论与实践, 2023, 18(02): 124-127. |
| [3] | 张音, 沈宏华, 许轶明, 任蕾, 李骏, 吴顺军, 凌小楠.肌少症合并腹型肥胖对住院老年人肌力及躯体功能的影响[J]. 内科理论与实践, 2023, 18(02): 76-82. |
| [4] | 中华医学会内分泌学分会.老年与儿童青少年糖尿病人群新型冠状病毒感染临床应对指南[J]. 内科理论与实践, 2023, 18(01): 10-12. |
| [5] | 张梦潇, 孙烁烁, 韦晓, 张少红, 陈国芳, 刘超.生酮饮食诱导db/db小鼠肝脏脂肪沉积[J]. 内科理论与实践, 2023, 18(01): 56-63. |
| [6] | 卜凡玉 郭晓峰 徐鹏 王进 薛明宇 潘筱云.抗生素骨水泥联合其他综合干预措施治疗糖尿病足骨髓炎[J]. 组织工程与重建外科杂志, 2022, 18(4): 328-. |
| [7] | 缪雅, 刘丽丽, 侯田志超, 严青华, 庞怡, 吴春晓, 程旻娜, 施燕, 黎衍云, 田景琰.上海糖尿病前期人群恶性肿瘤发病风险分析[J]. 内科理论与实践, 2022, 17(06): 435-440. |
| [8] | 阮铭, 侯田志超, 王海燕, 黎衍云, 周冰心, 包超慧, 秦洁洁, 王宇光, 方海, 朱伟嵘, 田景琰.糖尿病前期“治未病”的几何深度学习与计算医学研究展望[J]. 内科理论与实践, 2022, 17(06): 475-481. |
| [9] | 秦雪, 郭华, 张云云, 崔小川.C1q肿瘤坏死因子相关蛋白3与代谢相关疾病的研究进展[J]. 内科理论与实践, 2022, 17(06): 482-485. |
| [10] | 叶雅芬, 杨颖, 韩峻峰.脂肪组织衰老的细胞学改变及其分子机制研究进展[J]. 诊断学理论与实践, 2022, 21(05): 650-654. |
| [11] | 朱思毅 综述, 陈小松, 沈坤炜 审校.肥胖与早期乳腺癌预后和辅助治疗疗效的研究进展[J]. 外科理论与实践, 2022, 27(05): 468-472. |
| [12] | 许晴, 邵慧英, 陈帅, 全进伟, 周清芬, 王敏慧.延续健康教育和指导对干预2型糖尿病患者冠状动脉斑块进展的影响[J]. 内科理论与实践, 2022, 17(04): 330-333. |
| [13] | 高晶晶, 高艳虹.早发2型糖尿病流行病学、临床特征及病因机制的研究进展[J]. 内科理论与实践, 2022, 17(04): 344-348. |
| [14] | 孙洪平, 陈国芳, 刘超.植物性饮食与2型糖尿病的研究进展[J]. 内科理论与实践, 2022, 17(04): 349-352. |
| [15] | 宣呈杰, 卞冬生, 蒋咏梅, 陈宇菲, 金佳斌, 施咏梅.营养治疗对减重术后身体成分及静息能量消耗的影响[J]. 外科理论与实践, 2022, 27(03): 244-248. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
